Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study

Table 1 PCR primers and fragments for RAS/BRAF testing (KRAS exons 2, 3, and 4; NRAS exons 2, 3, and 4; and BRAF exon 15)

Exon	Primer	Fragment length (bp)
KRAS
Exon 2	F: 5′-TACTGGTGGAGTATTTGATAG-3′	248
Exon 2	R: 5′-TGGTCCTGCACCAGTAATATG-3′	248
Exon 3	F: 5′-GCACTGTAATAATCCAGACTGTG-3′	222
Exon 3	R: 5′-CCCACCTATAATGGTGAATATCTTC-3′	222
Exon 4	F: 5′-ATGACAAAAGTTGTGGACAGGTTTTGA-3′	284
Exon 4	R: 5′-ATGATTTTGCAGAAAACAGATCTGTATTTATTTCAG-3′	284
NRAS
Exon 2	F: 5′-GAACCAAATGGAAGGTCACACT-3′	243
Exon 2	R: 5′-CCTCACCTCTATGGTGGGATC-3′	243
Exon 3	F: 5′-TAGCATTGCATTCCCTGTGGTT-3′	258
Exon 3	R: 5′-CCTGTAGAGGTTAATATCCGCAA-3′	258
Exon 4	F: 5′-GCCACTGTACCCAGCCTAATCTTG-3′	287
Exon 4	R: 5′-CACATCTCTACCAGAGTTAATCAACTGATGC-3′	287
BRAF
Exon 15	F: 5′-CCTAAACTCTTCATAATGCTTGCTC-3′	211
Exon 15	R: 5′-GTGGAAAAATAGCCTCAATTCTTACC-3′	211

RAS rat sarcoma, BRAF v-raf murine sarcoma viral oncogene homolog B1, KRAS Kirsten rat sarcoma viral oncogene homolog, NRAS neuroblastoma RAS viral oncogene homolog

ISSN: 2523-3548